Navigation Links
EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease
Date:7/15/2009

VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability and safety.

The announcement came at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria where EnVivo presented its findings. EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognitive dysfunction associated with Alzheimer's disease and schizophrenia.

"EVP-6124 appears to be safe and was well tolerated over a month of dosing," commented Kees Been, CEO of EnVivo. "Most excitingly, the cognition improvement was observed on top of the effect of acetylcholinesterase inhibitors the patients were already taking. This is a strong indicator of a biologic and potentially useful clinical effect."

In this Phase Ib/IIa safety and biomarker study in patients with mild to moderate Alzheimer's disease already taking chronic acetylcholinesterase inhibitor (AChEI) therapy (donepezil or rivastigmine), three separate doses of EVP-6124 or a placebo dose were administered to a total of 48 subjects for 28 days. Safety and tolerability were determined by adverse events, clinical assessments, and laboratory studies. Cognition in AD patients was measured using the computerized CogState battery system and a group of traditional 'paper and pencil' cognition tests.

Minimal treatment-emergent adverse effects were observed during the trial and there were no serious adverse events. Improvement in a number of cognition measures in EVP-6124 treated patients were observed compared to placebo treated patients. These included measures of attention, verbal and language fluency, and executive function. Four of the eight cognition measures showed statistically significant dose-dependent effects and two others showed a trend towards improvement.

Based on the success of the trial, EnVivo plans to proceed to larger and longer Phase 2 studies to better define both the pro-cognitive effects of EVP-6124 as well as to measure its potential clinical benefit.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase I studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):